In November 2014, Arbutus signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc., to utilize our proprietary LNP delivery technology exclusively in Dicerna’s primary hyperoxaluria type 1 (PH1) development program.


The agreement provided Dicerna  access to Arbutus' third generation LNP technology for delivery of DCR-PH1 for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. In December 2015, Dicerna announced initiation of dosing in healthy volunteers with plans to initiate the Phase I clinical trial in patients with PH1. In October 2016, Dicerna announced the discontinuation of its DCR-PH1 program.